Prevalence

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
23andMe, Prevalence, Plasma, Genetics, NKG2D, Patient, SAN, Neoplasm, Data, Endothelium, Immunodeficiency, Cancer, Adenocarcinoma, PBMC, Biology, CD200, AACR, Therapy, Immunohistochemistry, NK, Carcinoma, The Cancer Genome Atlas, PD-1, Vaccine

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.

Key Points: 
  • Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.
  • ULBP6 is a stress-induced ligand that is upregulated on the surface of cancer cells and binds to the activating immunoreceptor NKG2D found on NK and T cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

CertiK Releases Hack3d: The Web3 Security Report for Q1 2024

Retrieved on: 
Wednesday, April 3, 2024
Ethereum, Bitcoin, CertiK, Web3, Hacks, Research, Solidity, Prevalence, Ecosystem, Cryptocurrency

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- CertiK, the industry leader in blockchain security, today announced the release of its flagship publication.

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- CertiK, the industry leader in blockchain security, today announced the release of its flagship publication.
  • Hack3d: The Web3 Security Report for Q1 2024 reports on the state of onchain security over the eventful first three months of the year.
  • Hack3d reports are the most detailed and authoritative security reports in the industry, providing the Web3 community the most comprehensive statistics on onchain hacks, scams, and exploits.
  • Key highlights from Hack3d Q1 2024 include:
    There was a total of $502,522,934 lost across 223 hacks, scams, and exploits in Q1 2024.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, April 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Disease, Organization, Prevalence, Caregiver, Patient, Knowledge, Social media, Research, FSR, Quality of life, Inflammation, Nursing

CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for patients, is proud to announce this year’s theme for April’s Sarcoidosis Awareness Month: Say Sarcoidosis. Sarcoidosis (pronounced SAR-COY-DOE-SIS) is an inflammatory disease of unknown cause characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Approximately 5-10% of all patients diagnosed will suffer from advanced sarcoidosis. Sarcoidosis affects the lungs in approximately 90% of cases, but it can affect almost any organ in the body and in more advanced or chronic cases can impact multiple organs at the same time. Despite its prevalence, sarcoidosis remains underrecognized and underdiagnosed, leading to delayed treatment and increased morbidity. It is estimated that 1.2 million people are affected worldwide. The Say Sarcoidosis campaign aims to shatter the silence and shine a light on the importance of speaking up about this often-misunderstood condition.

Key Points: 
  • CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving care for patients, is proud to announce this year’s theme for April’s Sarcoidosis Awareness Month: Say Sarcoidosis.
  • Approximately 5-10% of all patients diagnosed will suffer from advanced sarcoidosis.
  • The Say Sarcoidosis campaign aims to shatter the silence and shine a light on the importance of speaking up about this often-misunderstood condition.
  • For more information about Sarcoidosis Awareness Month and how to get involved with FSR’s Say Sarcoidosis campaign, please visit stopsarcoidosis.org/saysarcoidosis .

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
Wednesday, March 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

WatchGuard Threat Lab Analysis Shows Surge in Evasive Malware Supercharging an Already Powerful Threat Wave

Retrieved on: 
Wednesday, March 27, 2024
Maas, Organization, PowerShell, TLS, Prevalence, Intelligence, WatchGuard, Research, Software, Trojan, USF

The average malware detections per Firebox rose 80% from the previous quarter, illustrating a substantial volume of malware threats arriving at the network perimeter.

Key Points: 
  • The average malware detections per Firebox rose 80% from the previous quarter, illustrating a substantial volume of malware threats arriving at the network perimeter.
  • Zero-day malware detections jumped to 60% of all malware detections, up from 22% the previous quarter.
  • However, zero-day malware detections with TLS fell to 61%, which was a 10% decrease from Q3, showing the unpredictability of malware in the wild.
  • Both variants redirect users to malicious links, and both malware loaders attempt to load DarkGate malware on the victim’s computer.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Hepatitis, KPMG, GNI, Cirrhosis, Patient, Chronic obstructive pulmonary disease, Sale, Coagulopathy, Ernst & Young, Idiopathic pulmonary fibrosis, Fibrosis, Therapy, COPD, Marketing, Partnership, Arthur Andersen, Audit committee, SAN, Safety, CVR, CHB, Fatty liver disease, Prevalence, Pharmacy, Hospital, Research, Acquisition, TGF, Pirfenidone, GAAP, Toxicity, Inflammation, Accounting, Entecavir, Loss, Orthostatic hypertension, IPF, Partner, NASH, Category 1, Pharmaceutical industry

Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.

Key Points: 
  • Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.
  • In October 2023, Gyre (formerly known as Catalyst Biosciences, Inc. (“Catalyst”)) completed the previously announced business combination with GNI Group Ltd. (“GNI”) and related entities.
  • In October 2023, Gyre Pharmaceuticals completed enrollment of its Phase 3 trial in patients with CHB-associated liver fibrosis in the PRC.
  • Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.
    Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

Global Physical Therapy Software Market Research Report 2024: Employment Trends Catalyzing Growth, Technological Innovations - Long-term Forecast to 2028 and 2033 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Software, Technology, Health, Physical Therapy, Employment, PC, Growth, Prevalence, Therapy, EMR, Patient, Fracture, Bureau, Hospital, Health information management, Osteoporosis, Artificial intelligence, Movement

The "Physical Therapy Software Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Physical Therapy Software Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global physical therapy software market is undergoing a significant expansion, with projections indicating a rise from $24.56 billion in 2023 to an impressive $34.87 billion by 2028, representing a steady CAGR of 7.3%.
  • A projected growth in the employment of physical therapists is forecast to have a commensurate effect on the demand for physical therapy software.
  • The consistent evolution of the physical therapy software market is indicative of a growing recognition of the critical role such technologies play in modern healthcare.